Why the study?
Although PAR 2 expression increases in asthma and other inflammatory diseases, its regulation and role in asthma pathogenesis are not fully understood.
PAR2 plays a pro-inflammatory role in asthma pathogenesis and its expression on peripheral blood intermediate monocytes may serve as a useful biomarker for asthma severity.
PAR2 may represent an asthma therapeutic target; leaves open the need for clinical validation studies.
PAR 2 , a receptor activated by serine proteases, has primarily pro-inflammatory roles in the airways and may play a role in asthma pathogenesis. PAR 2 exerts its effects in the lungs through activation of a variety of airway cells, but also activation of circulating immune cells. There is evidence that PAR 2 expression increases in asthma and other inflammatory diseases, although the regulation of PAR 2 expression is not fully understood. Here we review the available literature on the potential role of PAR 2 in asthma pathogenesis and propose a model of PAR 2 -mediated development of allergic sensitization. We also propose, based on our previous work, that PAR 2 expression on peripheral blood monocyte subsets has the potential to serve as a biomarker of asthma severity and/or control.
No takes yet. Share an insight, caveat, or question.
Gandhi et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: